Assessment of radiation safety instructions to patients based on measured dose rates following prostate brachytherapy

Brachytherapy

Volumn 3, Issue 1, 2004, Pages 1-6

  Dauer, Lawrence T ^a   Zelefsky, Michael J ^a   Horan, Christopher ^a   Yamada, Yoshiya ^a   St Germain, Jean ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Brachytherapy; Dose rate; Prostate cancer; Radiation safety

Indexed keywords

IODINE 125; PALLADIUM 103;

ARTICLE; BODY WEIGHT; BRACHYTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PATIENT EDUCATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE; RADIATION EXPOSURE; RADIATION HAZARD; SAFETY; SKIN SURFACE; VALIDATION PROCESS;

BRACHYTHERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; PALLADIUM; PATIENT EDUCATION; PROSTATIC NEOPLASMS; RADIATION MONITORING; RADIOISOTOPES; RADIOMETRY;

EID: 1942489083     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2004.02.002     Document Type: Article

References (13)

1. Hilaris B., Holt J.G., St. Germain J. The use of iodine-125 for interstitial implants. DHEW Publication 76-8022. 1975;Food and Drug Administration, Rockville, MD.
2. Nuclear Regulatory Commission. 10CFR35.75: Release of individuals containing unsealed byproduct material or implants containing byproduct material. Code of Federal Regulations, Title 10, Volume 1, Revised as of January, 2001. Washington, DC: U.S. Government Printing Office.
3. National Council on Radiation Protection and Measurements. Precautions in the management of patients who have received therapeutic amounts of radionuclides. Report No. 37. 1970;National Council on Radiation Protection and Measurements, Bethesda, MD.
4. Holm H., Juul N., Pederson J., et al. Transperineal iodine-125 seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol. 130:1983;283-286.
5. Blasko J., Radge H., Schumacker D. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endocuriether Hyperthermia Oncol. 3:1987;131-139.
6. Stone N., Stock R. Permanent seed implantation for localized adenocarcinoma of the prostate. Curr Urol Rep. 3:2002;201-206.
7. Nuclear Regulatory Commission. NUREG-0980, Vol. 1, No. 6, Nuclear Regulatory Legislation, Atomic Energy Act, 1954, as amended. Washington DC: U.S. Nuclear Regulatory Commission June, 2002.
8. Nuclear Regulatory Commission. NUREG-1556, Vol. 9: Consolidated guidance about material licenses, program-specific guidance about medical use licenses. Washington DC: U.S. Nuclear Regulatory Commission June, 2002. p. U-1-U-27.
9. National Council on Radiation Protection and Measurements. Limitation of exposure to ionizing radiation. Report No. 116. 1993;National Council on Radiation Protection and Measurements, Bethesda, MD.
10. Anderson L., Nath R., Weaver K., et al. (Interstitial Collaborative Working Group). Interstitial brachytherapy, physical, biological, and clinical considerations. 1990;Raven Press, New York.
11. Memorial Sloan-Kettering Cancer Center. Patient education: Radioactive implants for the treatment of prostate cancer. 2003;1-13.
12. Smathers S., Wallner K., Korssjoen T., et al. Radiation safety parameters following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 45:1999;397-399.
13. Michalski J., Mutic S., Eichling J., et al. Radiation exposure to family and household members after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 56:2003;764-768.